title: Sensitivity of the recently infarcted heart to cardioplegic arrest. Beneficial effect of pretreatment with orotic acid.
abstract: The mortality and morbidity of cardiac operations are increased in the presence of an established, recent myocardial infarct. To help understand the mechanisms for this and to develop a therapeutic strategy, we studied the response of the recently infarcted canine heart to hypothermic cardioplegia and the effect of pretreatment with orotic acid. Orotic acid is a precursor of nucleic acids with the ability to enhance protein synthesis. In 21 greyhound dogs, a myocardial infarct was produced by ligation of the left anterior descending coronary artery. Ten of these then received oral orotic acid (100 mg/kg/day) for 4 days and 11 were untreated. A sham group of eight dogs had a thoracotomy only and therefore had normal hearts (normal group). Four days later, all dogs underwent 60 minutes of cardioplegic arrest at 28 degrees C. Before arrest, stroke work index was lower and myocardial oxygen consumption at comparable work levels was higher in both the orotic acid and untreated infarct groups than in the normal group. After arrest and reperfusion, there was a severe depression of ventricular function in the untreated infarct group, with only 18% recovery of prearrest stroke work. In the orotic acid infarct group, recovery of prearrest function (43%) was similar to that in the normal group (56%) and significantly greater than in the untreated infarct group (p less than 0.01). After reperfusion, the untreated infarct group had a lower oxygen consumption, lower myocardial levels of adenosine triphosphate and glycogen, and higher lactate and water contents than before arrest (all p less than 0.05). In the orotic acid and normal groups, these variables returned to prearrest levels. We conclude that an established, recent myocardial infarct places the noninfarcted myocardium under stress and increases its sensitivity to hypothermic cardioplegia. This sensitivity is markedly reduced by treatment with orotic acid.
authors.affiliation: Baker Medical Research Institute, Melbourne, Australia.
authors.forename: M A
authors.initials: MA
authors.lastname: Newman
authors.forename: X Z
authors.initials: XZ
authors.lastname: Chen
authors.forename: M
authors.initials: M
authors.lastname: Rabinov
authors.forename: J F
authors.initials: JF
authors.lastname: Williams
authors.forename: F L
authors.initials: FL
authors.lastname: Rosenfeldt
mesh_terms: D000818:Animals; D001834:Body Water / Q000378:metabolism; D002314:Cardioplegic Solutions; D004285:Dogs; D006324:Heart Arrest, Induced / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology*; D009206:Myocardium / Q000378:metabolism; D009963:Orotic Acid / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control*; D011292:Premedication; D015424:Reperfusion; D013318:Stroke Volume; D013997:Time Factors
chemical_list: D002314:Cardioplegic Solutions; D009963:Orotic Acid